1-2 of 2
Enrico Attingenti
Close
Sort by
Journal Articles

Elotuzumab, Lenalidomide, and Dexamethasone (EloRd) As Salvage Therapy for Patients with Multiple Myeloma: Italian, Multicenter, Retrospective Clinical Experience with 180 Cases Outside of Controlled Clinical Trials

Massimo Gentile, Daniele Derudas, MD, Monica Galli, MD, Stefano Rocco, Concetta Conticello, MD, Catello Califano, Nicola Giuliani, MD PhD, Silvia Mangiacavalli, MD, Enrico Attingenti, MD, Alessandra Lombardo, Marino Brunori, Elena Rossi, MD, Elisabetta Antonioli, MD, Roberto Ria, Renato Zambello, MD, Donatella Vincelli, MD, Angela Bonalumi, Agostina Siniscalchi, MD, Raffaella Stocchi, Massimo Martino, Stelvio Ballanti, Dominella Gangemi, Alfredo Gagliardi, MD, Vittorio Montefusco, MD, Barbara Gamberi, Alessandra Pompa, Anna Recchia, PhD BS, PharmD, Giovanni Tripepi, Ferdinando Frigeri, Sara Bringhen, MD, Elena Zamagni, MD, Francesca Patriarca, MD, Valerio De Stefano, MD, Francesco Di Raimondo, MD, Felicetto Ferrara, Fortunato Morabito, MD, Maria Teresa Petrucci, MD, Massimo Offidani, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2023.
https://doi.org/10.1182/blood-2018-99-115340
Published: 2018
Journal Articles

Rapid Transformation to Aggressive B-Cell Lymphoma, in a Case of Mixed Cellularity Hodgkin Lymphoma Subtype : A Rare Event

Antonio Abbadessa, Salvatore Iaccarino, Giuseppe Monaco, Maria Luigia Vigliotti, Mario Troiano, Enrico Attingenti
Journal: Blood
Blood (2008) 112 (11): 4831.
https://doi.org/10.1182/blood.V112.11.4831.4831
Published: 2008